Image

First-in-human, Study of MATTISSE® Tissue Engineering Chamber in Adult Female Patients Undergoing Breast Reconstruction After Mastectomy for Cancer

First-in-human, Study of MATTISSE® Tissue Engineering Chamber in Adult Female Patients Undergoing Breast Reconstruction After Mastectomy for Cancer

Recruiting
18 years and older
Female
Phase N/A

Powered by AI

Overview

This study is a first in human, two-stage single arm non-comparative study of safety and performance.

The aim of the study is to asses the safety and the clinical performance of a new device : the MATTISSE tissu engineering chamber.

Eligibility

Inclusion Criteria:

Criteria related to pathology:

  • Female patient over 18 Years old
  • Patient who required autologous breast reconstruction:
    • Immediate unilateral reconstruction after total mastectomy for early-stage breast cancer
    • Breast reconstruction after unilateral preventive total mastectomy
    • or delayed unilateral reconstruction after total mastectomy for early-stage breast cancer with a tissue expander implantation
    • or conversion from implant-based to autologous reconstruction: Patient who had a breast implant during a previous reconstruction after total mastectomy for cancer, and who needs to change it.
  • For patient with active cancer: Patient with early-stage cancer (stage 0, I or II,

    with tumor size < 50mm, without lymph-node involvement) needing oncological management that does not required radiotherapy after surgery on the breast area or on the flap donor site

  • Patient who required Nipple sparing (NSM) or Skin sparing mastectomy (SSM) with a unique surgical approach (same for mastectomy and implant) insertion; or implant removal for patient undergoing autologous conversion, or expender removal for patient undergoing differed reconstruction.
  • Autologous reconstruction using Lateral Intercostal Perforator (LICAP) flap or an intercostal thoracic artery perforation flap (LTAP) if oncological conditions do not allow for LICAP harvesting.
  • Patient medically fit for surgery without significant comorbidities
  • Breast cup-size less than D
  • Body mass index >20 kg/m2 or patient for whom sufficient flap volume is expected according to surgeon's assessment
  • Adequate hematopoietic functions

Criteria related to population:

  • Subjects who have given free, informed and written consent to participate in the study;
  • Patient able to answer questionnaires, able to communicate in the language of the study country;
  • Subjects affiliated to a social security schema or entitled to a social security scheme.

Non-inclusion Criteria:

Pathology related criteria:

  • Patient undergoing bilateral reconstruction
  • Patient undergoing bilateral preventive mastectomy
  • Patient undergoing simultaneous contralateral breast reduction, mastopexy, and augmentation
  • Previous history of radiotherapy on the breast area or on the flap donor site
  • Previous history of breast or axillary surgery that does not allow fat flap dissection
  • Presence of pacemaker or metallic prosthesis making patient unsuitable for MRI
  • Body mass index >30 kg/m2
  • Taking medication for weight loss at the time of inclusion visit
  • Presence of major medical conditions that may compromise patient's health and healing
  • Diabetes and a history of gestational diabetes
  • Active smoking
  • Microangiopathy, Vascular history and all systemic disease (systemic Raynaud's disease)
  • Patient with intertrigo or infection or alteration of the surgical site confirmed pre-operatively by clinical examination
  • Allergy to anesthetics or contrast media
  • Immunocompromised patient (HIV) or patient used immunosuppressants

Population related criteria

  • Pregnant patient
  • or breastfeeding patient or woman who has nursed a child three months within inclusion
  • Participation in a clinical trial in the 3 months prior to the initial visit
  • Predicted unavailability during study.
  • Patient deprived of liberty or under guardianship.
  • Patient unable to give consent

Medical device related criteria

  • Allergy to any of the components of the medical device.

EXCLUSION CRITERIA

  • Positive or suspicious extemporaneous sentinel node biopsy
  • Non integrity of LICAP and LTAP vessels, showed by the pre-operative doppler
  • Patient not yet implanted with MATTISSE®, whose cancer stage will finally require radiotherapy treatment

Study details
    Breast Cancer Female
    Breast Cancer Prevent
    Breast Reconstruction

NCT05460780

Quanta Medical

14 February 2024

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.